{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:46:32Z","timestamp":1770741992302,"version":"3.49.0"},"reference-count":80,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005677","name":"Deutsche Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung e.V.","doi-asserted-by":"publisher","award":["DJCLS R 13\/07"],"award-info":[{"award-number":["DJCLS R 13\/07"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Toxins"],"abstract":"<jats:p>Immunotoxins do not only bind to cancer-specific receptors to mediate the elimination of tumor cells through the innate immune system, but also increase target cytotoxicity by the intrinsic toxin activity. The plant glycoside SO1861 was previously reported to enhance the endolysosomal escape of antibody-toxin conjugates in non-hematopoietic cells, thus increasing their cytotoxicity manifold. Here we tested this technology for the first time in a lymphoma in vivo model. First, the therapeutic CD20 antibody obinutuzumab was chemically conjugated to the ribosome-inactivating protein dianthin. The cytotoxicity of obinutuzumab-dianthin (ObiDi) was evaluated on human B-lymphocyte Burkitt\u2019s lymphoma Raji cells and compared to human T-cell leukemia off-target Jurkat cells. When tested in combination with SO1861, the cytotoxicity for target cells was 131-fold greater than for off-target cells. In vivo imaging in a xenograft model of B-cell lymphoma in mice revealed that ObiDi\/SO1861 efficiently prevents tumor growth (51.4% response rate) compared to the monotherapy with ObiDi (25.9%) and non-conjugated obinutuzumab (20.7%). The reduction of tumor volume and overall survival was also improved. Taken together, our results substantially contribute to the development of a combination therapy with SO1861 as a platform technology to enhance the efficacy of therapeutic antibody-toxin conjugates in lymphoma and leukemia.<\/jats:p>","DOI":"10.3390\/toxins14070478","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:12:40Z","timestamp":1657757560000},"page":"478","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861"],"prefix":"10.3390","volume":"14","author":[{"given":"Hossein","family":"Panjideh","sequence":"first","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Institute of Diagnostic Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Augustenburger Platz 1, D-13353 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Niesler","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Institute of Diagnostic Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Augustenburger Platz 1, D-13353 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Weng","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Pharmazie, Freie Universit\u00e4t Berlin, K\u00f6nigin-Luise-Stra\u00dfe 2+4, D-14195 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9153-9594","authenticated-orcid":false,"given":"Hendrik","family":"Fuchs","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Institute of Diagnostic Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Augustenburger Platz 1, D-13353 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/j.biopha.2018.11.121","article-title":"The applications of anti-CD20 antibodies to treat various B cells disorders","volume":"109","author":"Payandeh","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_2","first-page":"588","article-title":"GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies","volume":"10","author":"Robak","year":"2009","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11523-017-0485-6","article-title":"Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma","volume":"12","author":"Dhillon","year":"2017","journal-title":"Target Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.2147\/DDDT.S212500","article-title":"Clinical application of obinutuzumab for treating chronic lymphocytic leukemia","volume":"13","author":"Luan","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.2217\/fon-2019-0193","article-title":"The role of obinutuzumab in the management of follicular lymphoma","volume":"15","author":"Townsend","year":"2019","journal-title":"Future Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12325-016-0451-1","article-title":"A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies","volume":"34","author":"Tobinai","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1182\/blood-2011-12-395541","article-title":"Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway","volume":"119","author":"Honeychurch","year":"2012","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/bjh.12427","article-title":"The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab","volume":"162","author":"Cheadle","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1007\/s11033-022-07280-w","article-title":"Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies","volume":"49","author":"Kawasaki","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s12185-022-03320-0","article-title":"Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors","volume":"115","author":"Yorozu","year":"2022","journal-title":"Int. J. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Hess, G., Huttmann, A., Witzens-Harig, M., Dreyling, M.H., Keller, U., Marks, R., Ernst, T., Pott, C., Viardot, A., and Frontzek, F. (2022). A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial. Br. J. Haematol.","DOI":"10.1111\/bjh.18161"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1080\/13543784.2017.1373087","article-title":"Combination therapy with the type II anti-CD20 antibody obinutuzumab","volume":"26","author":"Klein","year":"2017","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e692","DOI":"10.1097\/HS9.0000000000000692","article-title":"Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia","volume":"6","author":"Kutsch","year":"2022","journal-title":"Hemasphere"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Moreno, C., Greil, R., Demirkan, F., Tedeschi, A., Anz, B., Larratt, L., Simkovic, M., Novak, J., Strugov, V., and Gill, D. (2022). First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: Final analysis of the randomized, phase 3 iLLUMINATE trial. Haematologica.","DOI":"10.3324\/haematol.2021.279012"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.2147\/OTT.S134584","article-title":"Clinical targeting recombinant immunotoxins for cancer therapy","volume":"10","author":"Li","year":"2017","journal-title":"Onco. Targets Ther."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Phillips, G. (2013). Antibody Directed Delivery for Treatment of Cancer: Antibody Drug Conjugates and Immunotoxins. Antibody-Drug Conjugates and Immunotoxins, Springer.","DOI":"10.1007\/978-1-4614-5456-4"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-Drug Conjugates: A Comprehensive Review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"770","DOI":"10.2741\/3719","article-title":"Understanding rituximab function and resistance: Implications for tailored therapy","volume":"16","author":"Amoroso","year":"2011","journal-title":"Front. Biosci."},{"key":"ref_19","first-page":"5787","article-title":"Host-mediated antibody-dependent cellular cytotoxicity contributes to the in vivo therapeutic efficacy of an anti-CD7-saporin immunotoxin in a severe combined immunodeficient mouse model of human T-cell acute lymphoblastic leukemia","volume":"58","author":"Flavell","year":"1998","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1021\/mp400444q","article-title":"Modified trastuzumab and cetuximab mediate efficient toxin delivery while retaining antibody-dependent cell-mediated cytotoxicity in target cells","volume":"10","author":"Thakur","year":"2013","journal-title":"Mol. Pharm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/hon.2828","article-title":"Obinutuzumab-related adverse events: A systematic review and meta-analysis","volume":"39","author":"Amitai","year":"2021","journal-title":"Hematol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41408-018-0066-7","article-title":"The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma","volume":"8","author":"Huang","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3324\/haematol.2012.071092","article-title":"Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195\/rGEL), in patients with advanced myeloid malignancies","volume":"98","author":"Borthakur","year":"2013","journal-title":"Haematologica"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Fuchs, H. (2019). Dianthin and Its Potential in Targeted Tumor Therapies. Toxins, 11.","DOI":"10.3390\/toxins11100592"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00262-017-2013-z","article-title":"Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma","volume":"66","author":"Furness","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Polito, L., Mercatelli, D., Bortolotti, M., Maiello, S., Djemil, A., Battelli, M.G., and Bolognesi, A. (2017). Two Saporin-Containing Immunotoxins Specific for CD20 and CD22 Show Different Behavior in Killing Lymphoma Cells. Toxins, 9.","DOI":"10.3390\/toxins9060182"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6584","DOI":"10.2174\/1381612820666140826153913","article-title":"Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: A lethal cocktail with tumor specific efficacy","volume":"20","author":"Weng","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.3390\/toxins7051556","article-title":"Ribosome-inactivating and related proteins","volume":"7","author":"Schrot","year":"2015","journal-title":"Toxins"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0169-409X(97)00084-7","article-title":"Receptor-mediated targeted drug or toxin delivery","volume":"29","author":"Rihova","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1006\/scbi.1996.0013","article-title":"Why toxins!","volume":"7","author":"Fitzgerald","year":"1996","journal-title":"Semin. Cancer Biol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Fuchs, H., Niesler, N., Trautner, A., Sama, S., Jerz, G., Panjideh, H., and Weng, A. (2017). Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies. Biomedicines, 5.","DOI":"10.3390\/biomedicines5020014"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1002\/1878-0261.12115","article-title":"Targeted dianthin is a powerful toxin to treat pancreatic carcinoma when applied in combination with the glycosylated triterpene SO1861","volume":"11","author":"Bhargava","year":"2017","journal-title":"Mol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.bcp.2015.07.040","article-title":"Combinatorial approach to increase efficacy of Cetuximab, Panitumumab and Trastuzumab by dianthin conjugation and co-application of SO1861","volume":"97","author":"Weng","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jconrel.2018.02.031","article-title":"Targeted suicide gene transfections reveal promising results in nu\/nu mice with aggressive neuroblastoma","volume":"275","author":"Sama","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Zarinwall, A., Asadian-Birjand, M., Seleci, D.A., Maurer, V., Trautner, A., Garnweitner, G., and Fuchs, H. (2021). Magnetic Nanoparticle-Based Dianthin Targeting for Controlled Drug Release Using the Endosomal Escape Enhancer SO1861. Nanomaterials, 11.","DOI":"10.3390\/nano11041057"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jconrel.2012.10.002","article-title":"Saponins modulate the intracellular trafficking of protein toxins","volume":"164","author":"Weng","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7118","DOI":"10.1016\/j.bmc.2013.09.008","article-title":"The influence of saponins on cell membrane cholesterol","volume":"21","author":"Melzig","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.molonc.2012.12.004","article-title":"Targeted tumor therapy by epidermal growth factor appended toxin and purified saponin: An evaluation of toxicity and therapeutic potential in syngeneic tumor bearing mice","volume":"7","author":"Thakur","year":"2013","journal-title":"Mol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.2217\/fon.14.164","article-title":"Dianthin-EGF is an effective tumor targeted toxin in combination with saponins in a xenograft model for colon carcinoma","volume":"10","author":"Thakur","year":"2014","journal-title":"Future Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3109\/08923973.2014.971964","article-title":"Triterpenoid saponin augmention of saporin-based immunotoxin cytotoxicity for human leukaemia and lymphoma cells is partially immunospecific and target molecule dependent","volume":"37","author":"Holmes","year":"2015","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Bortolotti, M., Bolognesi, A., Battelli, M.G., and Polito, L. (2016). High in Vitro Anti-Tumor Efficacy of Dimeric Rituximab\/Saporin-S6 Immunotoxin. Toxins, 8.","DOI":"10.3390\/toxins8060192"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/sj.leu.2403378","article-title":"The conjugate Rituximab\/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine","volume":"18","author":"Polito","year":"2004","journal-title":"Leukemia"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1055\/s-0042-110495","article-title":"Saponins from Saponaria officinalis L. Augment the Efficacy of a Rituximab-Immunotoxin","volume":"82","author":"Thakur","year":"2016","journal-title":"Planta. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s40203-022-00120-6","article-title":"Ofatumumab and Granzyme B as immunotoxin against CD20 antigen","volume":"10","author":"Sefid","year":"2022","journal-title":"Silico Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jchromb.2017.11.038","article-title":"A novel adenine-releasing assay for ribosome-inactivating proteins","volume":"1072","author":"Weng","year":"2018","journal-title":"J. Chromatogr. B Analyt. Technol Biomed. Life Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.molonc.2012.01.004","article-title":"The toxin component of targeted anti-tumor toxins determines their efficacy increase by saponins","volume":"6","author":"Weng","year":"2012","journal-title":"Mol. Oncol."},{"key":"ref_47","unstructured":"Trautner, A. (2021). Mechanismen der Zielgerichteten Antitumoralen Wirksamkeit von Dianthin-Panitumumab-Konjugaten in Kombination Mit dem Glykosylierten Triterpenoid SO1861, Freie Universit\u00e4t Berlin."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Garcia-Perez, B.E., De la Cruz-Lopez, J.J., Castaneda-Sanchez, J.I., Munoz-Duarte, A.R., Hernandez-Perez, A.D., Villegas-Castrejon, H., Garcia-Latorre, E., Caamal-Ley, A., and Luna-Herrera, J. (2012). Macropinocytosis is responsible for the uptake of pathogenic and non-pathogenic mycobacteria by B lymphocytes (Raji cells). BMC Microbiol., 12.","DOI":"10.1186\/1471-2180-12-246"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.molimm.2015.04.018","article-title":"Active phagocytosis of Mycobacterium tuberculosis (H37Ra) by T lymphocytes (Jurkat cells)","volume":"66","author":"Zhang","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1111\/j.1742-4658.2005.04908.x","article-title":"Saporin and ricin A chain follow different intracellular routes to enter the cytosol of intoxicated cells","volume":"272","author":"Vago","year":"2005","journal-title":"FEBS J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.cbi.2008.08.004","article-title":"Soapwort saponins trigger clathrin-mediated endocytosis of saporin, a type I ribosome-inactivating protein","volume":"176","author":"Weng","year":"2008","journal-title":"Chem. Biol. Interact."},{"key":"ref_52","first-page":"97","article-title":"Endocytosis and intracellular localisation of type 1 ribosome-inactivating protein saporin-s6","volume":"26","author":"Bolognesi","year":"2012","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"834","DOI":"10.7150\/thno.12040","article-title":"A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab","volume":"5","author":"Chu","year":"2015","journal-title":"Theranostics"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s00262-009-0713-8","article-title":"Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts","volume":"58","author":"Ma","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"17943","DOI":"10.1038\/srep17943","article-title":"A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys","volume":"5","author":"Smith","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1126\/science.169.3940.68","article-title":"Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cells","volume":"169","author":"Moolten","year":"1970","journal-title":"Science"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1749-6632.1976.tb41740.x","article-title":"Immunotherapy of experimental animal tumors with antitumor antibodies conjugated to diphtheria toxin or ricin","volume":"277","author":"Moolten","year":"1976","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1600-065X.1982.tb00394.x","article-title":"Immunotoxins: Hybrid molecules combining high specificity and potent cytotoxicity","volume":"62","author":"Jansen","year":"1982","journal-title":"Immunol. Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1200\/JCO.1989.7.12.1932","article-title":"Immunotoxins: A clinical review of their use in the treatment of malignancies","volume":"7","author":"Hertler","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Baldo, B.A. (2022). Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies. Antibodies, 11.","DOI":"10.3390\/antib11010017"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Fuchs, H., Weng, A., and Gilabert-Oriol, R. (2016). Augmenting the Efficacy of Immunotoxins and Other Targeted Protein Toxins by Endosomal Escape Enhancers. Toxins, 8.","DOI":"10.3390\/toxins8070200"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1042\/bj3220719","article-title":"Characterization of a saporin isoform with lower ribosome-inhibiting activity","volume":"322","author":"Fabbrini","year":"1997","journal-title":"Biochem. J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1111\/j.1742-4658.2007.06008.x","article-title":"Lipopolyamine treatment increases the efficacy of intoxication with saporin and an anticancer saporin conjugate","volume":"274","author":"Geden","year":"2007","journal-title":"FEBS J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s12149-021-01607-6","article-title":"Targeted alpha immunotherapy of CD20-positive B-cell lymphoma model: Dosimetry estimate of (225)Ac-DOTA-rituximab using (64)Cu-DOTA-rituximab","volume":"35","author":"Lee","year":"2021","journal-title":"Ann. Nucl. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models","volume":"12","author":"Herter","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"Mossner","year":"2010","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1182\/blood-2015-03-634394","article-title":"Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia","volume":"127","author":"Byrd","year":"2016","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood-2014-07-586610","article-title":"Obinutuzumab (GA101) in relapsed\/refractory chronic lymphocytic leukemia: Final data from the phase 1\/2 GAUGUIN study","volume":"124","author":"Cartron","year":"2014","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc903","article-title":"Ligand-targeted therapeutics in anticancer therapy","volume":"2","author":"Allen","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.4049\/jimmunol.141.12.4410","article-title":"Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells","volume":"141","author":"Press","year":"1988","journal-title":"J. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0168-3659(95)00153-0","article-title":"Kinetic analysis of receptor-mediated endocytosis (RME) of proteins and peptides: Use of RME as a drug delivery system","volume":"39","author":"Kato","year":"1996","journal-title":"J. Control. Release"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.15232","article-title":"A tale of two antibodies: Obinutuzumab versus rituximab","volume":"182","author":"Freeman","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jconrel.2006.11.019","article-title":"A cleavable molecular adapter reduces side effects and concomitantly enhances efficacy in tumor treatment by targeted toxins in mice","volume":"117","author":"Fuchs","year":"2007","journal-title":"J. Control. Release"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/ijc.25123","article-title":"Epidermal growth factor receptor expression affects the efficacy of the combined application of saponin and a targeted toxin on human cervical carcinoma cells","volume":"127","author":"Bachran","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jconrel.2005.04.006","article-title":"Combined application of saponin and chimeric toxins drastically enhances the targeted cytotoxicity on tumor cells","volume":"106","author":"Heisler","year":"2005","journal-title":"J. Control. Release"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.3390\/toxins6051644","article-title":"Reporter assay for endo\/lysosomal escape of toxin-based therapeutics","volume":"6","author":"Thakur","year":"2014","journal-title":"Toxins"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pep.2013.07.004","article-title":"Small structural differences of targeted anti-tumor toxins result in strong variation of protein expression","volume":"91","author":"Thakur","year":"2013","journal-title":"Protein. Expr. Purif."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1002\/ijc.28893","article-title":"Immunotherapy of B-cell non-Hodgkin lymphoma by targeting the chemokine receptor CXCR5 in a preclinical mouse model","volume":"135","author":"Panjideh","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.bmc.2013.01.061","article-title":"Real-time analysis of membrane permeabilizing effects of oleanane saponins","volume":"21","author":"Mergel","year":"2013","journal-title":"Bioorg. Med. Chem."}],"updated-by":[{"DOI":"10.3390\/toxins14100703","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000}}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/14\/7\/478\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T14:05:20Z","timestamp":1754229920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/14\/7\/478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,13]]},"references-count":80,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["toxins14070478"],"URL":"https:\/\/doi.org\/10.3390\/toxins14070478","relation":{"correction":[{"id-type":"doi","id":"10.3390\/toxins14100703","asserted-by":"object"}]},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,13]]}}}